Abstract

The field of angiogenesis modulation is at a major crossroads. A tremendous advancement in basic science in this field is providing excellent support, though there is a lack of strong clinical support at this point with the exception of the recent data on anti-vascular endothelial growth factor (VEGF) as an adjunct to chemotherapy in solid tumor. Clinical outcome should include benefit/risk ratio, cost effectiveness, and hard end points including mortality, quality of life as opposed to tumor size reduction or decrease, and microvascular density with anti-angiogenesis agents.